Skip to content

News

Vulnerability in ARID1A-Mutant Cancer Cells Could Provide New Pathways for OCCC Treatment

Vulnerability in ARID1A-Mutant Cancer Cells Could Provide New Pathways for OCCC Treatment

OCRA grantees Dr. Rugang Zhang and Dr. Shuai Wu, both of The Wistar Institute, along with colleagues, have discovered a vulnerability in cancer cells that harbor certain genetic mutations. Their findings, which involve the ARID1A gene, point to potential new pathways of treatment for patients living with ovarian clear cell carcinoma (OCCC). What is an ARID1A mutation?   ARID1A … Continued

OCRA Awards Prizes in Ovarian Cancer Research

OCRA Awards Prizes in Ovarian Cancer Research

Each year, OCRA honors individuals doing important and notable work in the ovarian cancer field with a research prize to help propel their future discoveries. Individuals are selected by members of OCRA’s Scientific Advisory Committee. Dr. Sarah Adams Awarded Liz Tilberis Research Prize for Outstanding Early Career Investigators The Liz Tilberis Research Prize is awarded … Continued

Xueyang Yu, PhD., Ovarian Cancer Researcher | Meet a Scientist

Xueyang Yu, PhD., Ovarian Cancer Researcher | Meet a Scientist

Dr. Xueyang Yu, of Massachusetts Institute of Technology, is a 2021 recipient of OCRA’s Ann and Sol Mentored Investigator Award. Her project, “Macrophage Control of the Microenvironment Drives HGSOC Progression,” explores how tumor microenvironments influence disease progression for high-grade serous ovarian carcinoma, the most common type of ovarian cancer. What initially sparked your interest in … Continued

The Overview: February 2021

The Overview: February 2021

We have great hope for the year ahead, and much of that is buoyed by what we accomplished, with your help, in 2020. A quick look back at the numbers… Thank you for everything you have done to make this happen. We hope you enjoy reading about what lies ahead. RESEARCH ADVOCACY PATIENT SUPPORT & … Continued

Racial Disparities in Ovarian Cancer are Real

Racial Disparities in Ovarian Cancer are Real

Dr. Dineo Khabele, Professor and Chair of the Department of Obstetrics & Gynecology at Washington University School of Medicine in St. Louis and member of OCRA’s Scientific Advisory Committee, spoke at our 2020 Ovarian Cancer National Conference about the racial disparities in ovarian cancer incidences and outcomes. While there are more documented cases of ovarian … Continued

OCRA Awards Millions in New Ovarian Cancer Research Grants

OCRA Awards Millions in New Ovarian Cancer Research Grants

Despite the challenges of fundraising during a global pandemic, your generous support allowed us to fund 16 top scientists at 14 esteemed medical centers across the globe. They will investigate important issues across the ovarian cancer landscape in this coming year. These grants enable the brightest minds in cancer research to tackle long-standing issues like … Continued

OCRA-Funded Research Provides a New Understanding of Ovarian Cancer Biology

OCRA-Funded Research Provides a New Understanding of Ovarian Cancer Biology

OCRA-funded researcher Anil K. Sood, M.D., lead and senior author, and Sanghoon Lee, Ph.D., first author, both at MD Anderson Cancer Center, along with colleagues, identified potential biomarkers in subgroups of high-grade serous ovarian cancer (HGSC). Biomarkers are unique biological indicators of an event, or the presence of a substance in the body. Biomarkers are useful … Continued

The COVID-19 Vaccine and Ovarian Cancer: Resources and Information

The COVID-19 Vaccine and Ovarian Cancer: Resources and Information

The rollout of COVID-19 vaccines in the United States has many feeling hopeful about the possibility of gaining some protection against the virus. But as with any new medical advancement, it is not uncommon for people to have questions about its safety and efficacy. And for those who are living with ovarian cancer, there are … Continued

Oral Contraceptives Tied to Lower Long-Term Ovarian Cancer Risk

Oral Contraceptives Tied to Lower Long-Term Ovarian Cancer Risk

A recent study, published in Cancer Research and reported in The New York Times, suggests that risk-reduction associated with oral contraceptive use can last a lifetime. The link between lower ovarian and endometrial cancer risk and oral contraceptive use has long been established; however, it was unclear how long after taking oral contraceptives a woman … Continued

OCRA-Funded Research Discoveries in 2020

OCRA-Funded Research Discoveries in 2020

It’s hard to believe 2020 is almost over, and what a year it’s been.  Despite the challenges wrought by the pandemic, we’re grateful to report that thanks to your support, OCRA grantees made great strides in ovarian cancer discoveries, bringing us ever closer to improving care and defeating this devastating disease: Revealed two cells of origin for high-grade serous ovarian cancer — … Continued

The Overview: December 2020

The Overview: December 2020

We’re probably all ready to say goodbye to 2020, if we have to be honest with ourselves. And yet, we can’t look back and say that the year was entirely bad. With your support, OCRA actually accomplished quite a lot and we have much for which to feel hopeful. RESEARCH ADVOCACY PATIENT SUPPORT & PROGRAMS WAYS TO GIVE … Continued

OCRA Research Investigates Role of Extracellular Vesicles in Cancer Research

OCRA Research Investigates Role of Extracellular Vesicles in Cancer Research

OCRA-funded researchers Dr. Sunila Pradeep and Dr. Pradeep Chaluvally-Raghavan, both at the Medical College of Wisconsin, along with colleagues, summarized recent literature on the function of extracellular vesicles “in regulating the critical processes associated with cancer progression.” Their review, published in the journal Cancers, also provides insights on how these vesicles are used as biomarkers … Continued

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

Our website uses cookies to ensure you get the best experience. By continuing to use this website, you indicate that you have read and agree to our Terms of Use and Privacy Policy.